In the present study, we demonstrated that human GBM cells stably overexpressing EGFRvIII are resistant to up to 200 μM TMZ, the standard chemotherapeutic drug in GBM treatment, despite EGFR− cells. The gene discussed is EGFR; the disease is glioblastoma.